Tratamiento
del diabético tipo 2 Insulinas: tratamiento único
y/o en combinación
BIBLIOGRAFÍA
1.
DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes
mellitus. Scientific review. JAMA 2003; 289: 2254-64.
2. Halimi S, Corticelli
P, Benhamou PY. Combination of insulin and sulfonylureas: A literature review.
Am J Med 1991; 90 (suppl 6A): 83s-6s.
3. Del Pratto S. Rationale for the Association
of Sulfonylureas and Insulin. Am J Med 1991; 90 (suppl 6A): 77s-82s.
4. Peters
AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes.
Ann Int Med 1991; 115: 45-53.
5. Pugh JA, Wagner MJ, Sawyer J, Ramirez G, Tuley
M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM
patient? A meta-analysis. Diabetes Care 1992; 15: 953-9.
6. Chow CC, Tsang
LWW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation
of oral hypoglycaemic agents in the treatment of secondary failure in NIDDM patients.
Diabetes Care 1995; 18: 307-14.
7. Landstent-Hallin L, Adamson U, Arner P,
Bolinder J, Lins PE. Comparison of bedtime NPH or preprandial regular insulin
combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995;
18: 1183-6.
8. Johnson JL, Wolf SL, Kanbadi UM. Efficacy of insulin and sulfonylurea
therapy in type II Diabetes. A meta-analysis of the randomized placebo-controlled
trials. Arch Intern Med 1996; 156: 259-64.
9. Yki-Järvinen H, Kauppila
M, Kujansuu E, Lahti J, et al. Comparison of insulin regimes in patients with
non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-33.
10.
Groop L, Widen E, Ekstrand A, Salorant C, Franssila-Kaluunki A, Schalin-Jantti
C, Eiksson JG. Morning or bedtime NPH insulin combined with sulfonylurea treatment
of NIDDM. Diabetes Care 1992; 15: 831-4.
11. Soneru IL, Agrawal L, Murphy JC,
Lawrence AM, Abraira C. Comparison of morning and bedtime insulin with and without
glyburide in secondary sulfonylurea failure. Diabetes Care 1993; 16: 896-901.
12.
Slama G. The insulin sparing effect of metformin in insulin-treated diabetic patients.
Diabet & Metab 1991; 17: 241-3.
13. Hanuschak LN. Metformin useful in Combination
with exogenous insulin. Diabetes Care 1996; 19: 671-72.
14. Giugliano D, Quatraro
A, Consoli G et al. Metformin for obese, insulin-treated diabetic patients: imprevementes
in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol
1993; 44: 107-12.
15. Fernández Fernández I, Villafuerte Fernández
I. En el paciente con diabetes mellitus tipo 2 con mal control bajo tratamiento
insulínico ¿el tratamiento con metformina mejora el control glucémico?.
Atención Primaria Basada en la Evidencia. FMC 2001; 8: 7-8.
16. Wulfele
MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B et al. Combination
of insulin and metformin in the treatment of type 2 diabetes. Diabetes care 2002;
25: 2133-40.
17. Hermann LS, Kalen J, Katzman P, Lager I, Nilsson A, Norrhamn
O, Sartor G, Ugander L. Long-term glycaemic improvement after addition of metformin
to insulin in insulin-treated obese type 2 diabetes patients. Diabetes Obes M
etab 2001; 3: 428-34.
18. Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt
JA. A double-blind placebo-controlled trial evaluating the safety and efficacy
of acarbose for the treatment of patients with insulin-requiring type II Diabetes.
Diabetes Care 1995; 18: 928-32.
19. Serrano Rios M. Acarbose and insulin therapy
in type I Diabetes Mellitus. Eur J Clin Invest 1994; 24 (suppl 3): 36-9.
20.
Escobar-Jiménez F, De Leiva A, Piñón F, et al. Eficacia clínica
y tolerancia de la acarbosa en el tratamiento de pacientes diabéticos dependientes
de insulina (tipo I). Med Clin (Barc) 1993; 100: 488-91.
21. Tattersall R.
Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes.
Diabetic Med 1993; 10: 688-93.
22. Rosentock J, Einhorn D, Hershon K, Glazer
NB, Yu S; Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in
type 2 diabetes: a randomised, placebo-controlled study in patients receiving
stable insulin therapy. In J Clin Pract 2002; 56: 251-7.
23. Yki-Järvinen
H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime
insulin regimes in patients with type 2 diabetes mellitus. A randomized controlled
trial. Ann Intern Med 1999; 130: 389-96.
24. Yki-Järvinen H. Combination
therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-67.
25.
Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycaemia and better
post-dinner glucose control with bedtime insulin glargine compared with bedtime
NPH insulin during combination Therapy in type 2 diabetes: HOE 901/3002 Study
Group. Diabetes Care 2000; 23: 1130-6.
26. Fritsche A, Schweitzer MA, Haring
HU; 4001 study Group. Glimepiride combined with morning insulin glargine, bedtime
neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with
type 2 diabetes. A randomized controlled trial. Ann Intern Med 2003; 138: 952-9.
27.
Chan JL, Abrahamson MJ. Pharmacological Management of Type 2 Diabetes Mellitus:
Rationale for Rational Use of Insulin. Mayo Clin Proc 2003;78:459-67.
28. Penfornis
A, Millot L . Initiating insulin treatment in insulin-requiring type 2 diabetic
patients: comparative efficiency and cost of outpatient and inpatient management.
INNOV Study Group. Diabetes Metab 1998; 24:137-42.
29. Fernández Fernández
I, Franch Nadal J, Martín Manzano JL, Navarro Pérez J, Orozco Beltrán
D, Vázquez Garijo P. Programa del adulto: Diabetes mellitus. Programas
Básicos de salud de semFYC. Ed Doyma, Madrid, 1998.
indice
